Types of Market Access Consulting Firms — and When to Use Each

A practical taxonomy of the market access consulting landscape: dedicated access and HEOR specialists, strategy houses, policy advisors, data-integrated giants, boutiques, and access agencies — with guidance on matching firm type to the problem.

Published July 21, 2026

Market Access & HEOR

Market access consulting firms cluster into six types: dedicated access and HEOR specialists, strategy consultancies with pricing and access practices, policy-focused advisors, data- and services-integrated giants, focused boutiques, and payer-communications agencies. The right choice depends less on firm prestige than on the shape of the problem — evidence generation calls for an HEOR specialist, a pricing decision with board visibility calls for a strategy house, a Medicare policy question calls for a policy shop, and executional payer campaigns call for an access agency. Most manufacturers use several types across a product’s lifecycle, and the market itself is consolidating fast enough that last year’s org chart may no longer apply.

Why the distinction matters now

Demand for market access work keeps climbing. The Inflation Reduction Act’s Medicare Drug Price Negotiation Program is now in its third cycle: in January 2026 CMS selected 15 more drugs — including, for the first time, Part B drugs — with negotiations running through 2026 and new maximum fair prices effective in 2028. Every selected manufacturer, and every manufacturer modeling whether a pipeline asset could be selected, needs pricing strategy, evidence, and policy analysis it may not carry in-house.

At the same time, the supply side is consolidating. Omnicom realigned Entrée Health, McCann Health Managed Markets, Mosaic Group, Valuate Health Consultancy, and Archbow Consulting into a single Omnicom Health Market Access division. Herspiegel acquired UK HEOR firm FIECON in April 2025 and Decisive Consulting weeks later as part of a private-equity-backed platform build. Similar PE-driven roll-ups produced Lumanity, Petauri, and others. Knowing which type of firm you are actually buying — beneath the holding-company brand — matters more than ever.

The six firm types

1. Dedicated market access and HEOR specialists

These firms do access work as their core business: payer strategy, pricing and contracting, health economics and outcomes research (HEOR), value dossiers, and HTA submissions.

Representative firms: Precision AQ, Lumanity, Cencora (Xcenda), OPEN Health, Evidera, Certara, Analysis Group, Genesis Research Group, Maple Health Group, and Curta.

Use when: you need payer-facing evidence and materials — economic models, AMCP-format dossiers, HTA submissions, payer advisory boards — or a full access strategy grounded in payer insight. Several of these firms staff former payer decision-makers precisely for that reason.

2. Strategy consultancies with pricing and access practices

General or life-sciences strategy houses whose access work is one practice among several. They bring cross-functional rigor and are comfortable in boardrooms where access questions meet portfolio and deal questions.

Representative firms: ZS Associates, Simon-Kucher, L.E.K. Consulting, Charles River Associates, Trinity Life Sciences, ClearView Healthcare Partners, Putnam, Blue Matter Consulting, Health Advances, and Kx Advisors.

Use when: the question is strategic and consequential — global pricing corridors, launch sequencing, whether an asset’s access profile supports a deal or an indication expansion. These firms excel at decisions; they typically hand off long-run evidence generation and payer materials to type-1 or type-6 partners.

3. Policy-focused advisors

Washington-centric firms fluent in CMS rulemaking, Medicare and Medicaid mechanics, 340B, and — increasingly — IRA negotiation dynamics.

Representative firms: Avalere Health, ADVI Health, and Magnolia Market Access.

Use when: government programs drive your economics. IRA selection modeling, maximum-fair-price impact analysis, Medicaid rebate questions, and policy scenario planning are this segment’s home turf, and it is often engaged alongside a type-1 or type-2 firm rather than instead of one.

4. Data- and services-integrated giants

Large organizations where consulting sits next to proprietary data assets, CRO operations, or distribution and patient-services infrastructure.

Representative firms: IQVIA, ICON plc, EVERSANA, Cencora (via Xcenda), and IntegriChain’s Blue Fin Group advisory arm.

Use when: the work depends on data at scale (claims, prescription, payer coverage data) or must connect directly to execution — field teams, hubs, 3PL, gross-to-net operations. The integration is the value; the trade-off is that recommendations may gravitate toward the parent’s own service lines, so governance of the engagement matters.

5. Focused boutiques

Small firms with deep specialization by therapeutic area or by function.

Representative firms: The Dedham Group (oncology and specialty access), Archbow Consulting (distribution, pharmacy, and patient-access operations), Two Labs (launch planning and execution), Innopiphany, AESARA, and Alira Health.

Use when: the problem is narrow and depth beats breadth — designing a limited-distribution network, an oncology pathways strategy, or a first launch at an emerging biotech that needs senior hands-on help rather than a large team. Note that many boutiques now sit inside larger platforms (Dedham within Norstella, Archbow within Omnicom), which can bring adjacent capabilities but also changes independence.

6. Payer-communications and access agencies

Agency-model firms that translate access strategy into payer-facing campaigns, value communications, and account-team tools, often within healthcare advertising holding companies.

Representative firms: Omnicom Health Market Access (Entrée Health), Valuate Health Consultancy, Payer Sciences, and AESARA in its agency work.

Use when: strategy exists and the need is execution — payer value decks, formulary pull-through materials, account-management programs. Agencies are typically retained continuously through launch and lifecycle, where consultancies are engaged by project.

Matching firm type to problem

Situation	First call	Often paired with
Value dossier, economic model, HTA submission	Access/HEOR specialist	Policy advisor (for US government angles)
Global pricing decision, launch sequencing	Strategy consultancy	Access/HEOR specialist
IRA negotiation exposure, Medicare policy shift	Policy advisor	Strategy consultancy
Data-heavy payer analytics, execution-linked access	Integrated giant	Boutique for independent check
Distribution design, oncology pathways, first launch	Focused boutique	Access agency at launch
Payer campaign, pull-through, account tools	Access agency	Access/HEOR specialist for evidence

Practical takeaways

Three habits make these engagements work better. First, scope by deliverable, not by firm category: a “market access strategy” from a strategy house, an HEOR shop, and an agency are three different documents, so write down what payer-facing artifact you expect at the end. Second, check what you are buying beneath the brand — consolidation means the boutique you used three years ago may now be a division of a holding company with different staffing and different incentives; ask who will actually be on the team. Third, plan for pairs: the most common failure mode is hiring one firm type and expecting another type’s output, when a specialist-plus-agency or strategy-plus-policy pairing would have matched the lifecycle stage. Vendor profiles with current ownership, service lines, and recent M&A are the fastest way to make that first cut before you ever sit through a capabilities deck.